Authorization of anastrazole to prevent breast cancer in postmenopausal women: a bad idea

Abstract

Anastrazole has recently been approved for the prevention of breast cancer in high-risk women in the UK. When given to high-risk women anastrazole halves the risk of developing breast cancer but doesn’t reduce the risk of breast cancer death and is associated with significant harms. Women need to be counselled about both the benefits and risks associated with anastrazole use to enable an informed treatment choice.

摘要

阿那曲唑最近被批准用于预防英国高危女性患乳腺癌。当高危女性服用阿那曲唑时, 患乳腺癌的风险会减半, 但并不能降低乳腺癌死亡的风险, 而且会带来很大的危害。需要就应用阿那曲唑的益处和风险向女性提供咨询, 以便她们做出明智的治疗选择。

Keywords:

• Anastrazole
• breast cancer
• prevention
• risks
• benefits
• informed choice

Potential conflict of interest

No potential conflict of interest was reported by the authors.

Source of funding

Nil.